Daesung Microbiological Labs (A036480) Stock Overview
Manufactures and sells vaccines for swine, poultry, canine, cattle, and fish in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
A036480 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Daesung Microbiological Labs. Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩7,700.00 |
| 52 Week High | ₩10,960.00 |
| 52 Week Low | ₩6,100.00 |
| Beta | 0.24 |
| 1 Month Change | -15.85% |
| 3 Month Change | 5.34% |
| 1 Year Change | -9.09% |
| 3 Year Change | -22.54% |
| 5 Year Change | -61.69% |
| Change since IPO | -58.15% |
Recent News & Updates
Recent updates
Daesung Microbiological Labs (KOSDAQ:036480) Is Carrying A Fair Bit Of Debt
Aug 06
Is Daesung Microbiological Labs (KOSDAQ:036480) Using Too Much Debt?
May 08Is The Market Rewarding Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:036480) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?
Mar 15We're Not Counting On Daesung Microbiological Labs (KOSDAQ:036480) To Sustain Its Statutory Profitability
Feb 17
Is Daesung Microbiological Labs (KOSDAQ:036480) A Risky Investment?
Jan 21Update: Daesung Microbiological Labs (KOSDAQ:036480) Stock Gained 83% In The Last Five Years
Dec 31Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:036480) Is Up But Financials Look Inconsistent: Which Way Is The Stock Headed?
Dec 10Here's Why We Don't Think Daesung Microbiological Labs's (KOSDAQ:036480) Statutory Earnings Reflect Its Underlying Earnings Potential
Nov 19Shareholder Returns
| A036480 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 3.9% | 5.6% | 5.8% |
| 1Y | -9.1% | 40.9% | 138.3% |
Return vs Industry: A036480 underperformed the KR Biotechs industry which returned 40.9% over the past year.
Return vs Market: A036480 underperformed the KR Market which returned 138.3% over the past year.
Price Volatility
| A036480 volatility | |
|---|---|
| A036480 Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 9.2% |
| 10% most volatile stocks in KR Market | 16.2% |
| 10% least volatile stocks in KR Market | 4.6% |
Stable Share Price: A036480 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A036480's weekly volatility has increased from 6% to 12% over the past year, but is still lower than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1966 | n/a | Hang-Won Cho | www.dsmbio.co.kr |
Daesung Microbiological Labs. Co., Ltd. manufactures and sells vaccines for swine, poultry, canine, cattle, and fish in South Korea. It offers antibiotics and antibacterials, parasiticides and disinfectants, probiotics and enzyme products, and nutrients and pharmaceuticals. The company also exports its products.
Daesung Microbiological Labs. Co., Ltd. Fundamentals Summary
| A036480 fundamental statistics | |
|---|---|
| Market cap | ₩29.26b |
| Earnings (TTM) | ₩598.19m |
| Revenue (TTM) | ₩25.99b |
Is A036480 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A036480 income statement (TTM) | |
|---|---|
| Revenue | ₩25.99b |
| Cost of Revenue | ₩19.67b |
| Gross Profit | ₩6.32b |
| Other Expenses | ₩5.72b |
| Earnings | ₩598.19m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 157.42 |
| Gross Margin | 24.32% |
| Net Profit Margin | 2.30% |
| Debt/Equity Ratio | 55.4% |
How did A036480 perform over the long term?
See historical performance and comparisonDividends
Does A036480 pay a reliable dividends?
See A036480 dividend history and benchmarks| Daesung Microbiological Labs dividend dates | |
|---|---|
| Ex Dividend Date | Dec 29 2025 |
| Dividend Pay Date | Apr 24 2026 |
| Days until Ex dividend | 112 days |
| Days until Dividend pay date | 4 days |
Does A036480 pay a reliable dividends?
See A036480 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/19 00:36 |
| End of Day Share Price | 2026/04/17 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Daesung Microbiological Labs. Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.